Pasar al contenido principal

METALLOFAMACOS COMO CONMUTADORES SENSIBLES AL PH PARA SU USO EN NANOMEDICINA

CTQ2017-84932-P

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D (Excelencia / Generación de Conocimiento)
Año convocatoria 2017
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION IMDEA NANOCIENCIA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Structurally Strained Half-Sandwich Iridium(III) Complexes As Highly Potent Anticancer Agents

  • Carrasco, Ana C.
  • Rodriguez-Fanjul, V.
  • Habtemariam, Abraha
  • Pizarro, Ana M.
Six complexes of formula [Ir(η5:κ1-C5Me4CH2py)(C,N)]PF6, where C5Me4CH2py is 2-((2,3,4,5-tetramethylcyclopentadienyl)methyl)pyridine, and C,N is 2-phenylpyridine (1), 7,8-benzoquinoline (2), 1-phenylisoquinoline (3), 2-(p-tolyl)pyridine (4), 4-chloro-2-phenylquinoline (5), or 2-(2,4-difluorophenyl)pyridine (6), have been synthesized. The cyclopentadienyl ligand bears a tethered pyridine that binds to the metal center, resulting in an Ir(η5:κ1-C5Me4CH2pyN) tether-ring structure, as confirmed by the X-ray crystal structures of 1, 2, 4, 5, and 6. Nontether versions of 1 and 2 were synthesized to aid unambiguous correlation between structure and activity. While nontether complexes are highly potent toward MCF7 cancer cells (similar to cisplatin), complexes bearing the tether-ring structure, 1–6, are exceptionally more potent (1–2 orders of magnitude). Additionally, 1–6 disrupt mitochondrial membrane potential (ΔΨm) and induce oxidative stress. Internalization studies strongly correlate intracellular accumulation and anticancer activity in tether and nontether complexes. We present a new class of organo-iridium drug candidates bearing a structural feature that results in a leap in anticancer potency., We acknowledge funding from the EC (FP7-PEOPLE-2013-CIG, no. 631396), and from the Spanish MINECO (RYC-2012-11231, CTQ2014-60100-R, SEV-2016-0686, and CTQ2017-84932-P). A.H. was supported by the Comunidad Autónoma de Madrid (Professorship of Excellence 2016-T3/IND-2054).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Unambiguous Intracellular Localization and Quantification of a Potent Iridium Anticancer Compound by Correlative 3D Cryo X-Ray Imaging

  • Conesa, José J.
  • Carrasco, Ana C.
  • Rodríguez‐Fanjul, Vanessa
  • Yang, Yang
  • Carrascosa, José L.
  • Cloetens, Peter
  • Pereiro, Eva
  • Pizarro, Ana M.
The iridium half‐sandwich complex [Ir(η5:κ1‐C5Me4CH2py)(2‐phenylpyridine)]PF6 is highly cytotoxic: 15–250× more potent than clinically used cisplatin in several cancer cell lines. We have developed a correlative 3D cryo X‐ray imaging approach to specifically localize and quantify iridium within the whole hydrated cell at nanometer resolution. By means of cryo soft X‐ray tomography (cryo‐SXT), which provides the cellular ultrastructure at 50 nm resolution, and cryo hard X‐ray fluorescence tomography (cryo‐XRF), which provides the elemental sensitivity with a 70 nm step size, we have located the iridium anticancer agent exclusively in the mitochondria. Our methodology provides unique information on the intracellular fate of the metallodrug, without chemical fixation, labeling, or mechanical manipulation of the cells. This cryo‐3D correlative imaging method can be applied to a number of biochemical processes for specific elemental localization within the native cellular landscape., We acknowledge funding from the EC (FP7‐PEOPLE‐2013‐CIG, No. 631396), from the MINECO of Spain (RYC‐2012–11231, CTQ2014‐60100‐R, SEV‐2016‐0686, BFU 2014–54181‐P, and CTQ2017‐84932‐P), and from the Comunidad Autónoma de Madrid (S2013/MIT‐ 2850). Cryo‐SXT experiments were performed at MISTRAL beamline at ALBA Synchrotron with the collaboration of ALBA staff (2017022061). Cryo‐XRF experiments were performed at ID16A beamline at ESRF Synchrotron with the collaboration of ESRF staff, in the frame of proposals LS2767 (doi:10.15151/ESRF‐ES‐112668425) and IHLS3102 (doi:10.15151/ESRF‐ES‐103850884).